BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 11368286)

  • 1. Levosimendan.
    Figgitt DP; Gillies PS; Goa KL
    Drugs; 2001; 61(5):613-27; discussion 628-9. PubMed ID: 11368286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 3. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA; Wagstaff AJ
    Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
    Cavusoglu Y
    Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levosimendan: implications for clinicians.
    McBride BF; White CM
    J Clin Pharmacol; 2003 Oct; 43(10):1071-81. PubMed ID: 14517189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review on Role of the Calcium Sensitive Inotropic Agent, Levosimendan and Its Metabolites.
    Asif M
    Mini Rev Med Chem; 2018; 18(16):1354-1362. PubMed ID: 27594341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
    Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP
    Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levosimendan and calcium sensitization of the contractile proteins in cardiac muscle: impact on heart failure.
    Kota B; Prasad AS; Economides C; Singh BN
    J Cardiovasc Pharmacol Ther; 2008 Dec; 13(4):269-78. PubMed ID: 19087950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.
    García González MJ; Domínguez Rodríguez A
    Am J Cardiovasc Drugs; 2006; 6(2):69-75. PubMed ID: 16555860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of Levosimendan in intensive care treatment of myocardial insufficiency].
    Rehberg S; Ertmer C; Van Aken H; Lange M; Bröking K; Morelli A; Westphal M
    Anaesthesist; 2007 Jan; 56(1):30-43. PubMed ID: 17131137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between the pharmacokinetics of levosimendan and its effects on cardiovascular system.
    Antoniades C; Antonopoulos AS; Tousoulis D; Bakogiannis C; Stefanadi E; Stefanadis C
    Curr Drug Metab; 2009 Feb; 10(2):95-103. PubMed ID: 19275545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel biologic mechanisms of levosimendan and its effect on the failing heart.
    Parissis JT; Andreadou I; Bistola V; Paraskevaidis I; Filippatos G; Kremastinos DT
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1143-50. PubMed ID: 18616411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inoprotection: the perioperative role of levosimendan.
    Soeding PE; Royse CF; Wright CE; Royse AG; Angus JA
    Anaesth Intensive Care; 2007 Dec; 35(6):845-62. PubMed ID: 18084975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacology of levosimendan.
    Antila S; Sundberg S; Lehtonen LA
    Clin Pharmacokinet; 2007; 46(7):535-52. PubMed ID: 17596101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of acute cardiac failure by intracoronary administration of levosimendan.
    Caimmi PP; Kapetanakis EI; Beggino C; Molinari C; Giustini G; Crosio E; Reposo G; Micalizzi E; Vacca G; Grossini E
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):246-53. PubMed ID: 21654504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan: from basic science to clinical practice.
    Parissis JT; Rafouli-Stergiou P; Paraskevaidis I; Mebazaa A
    Heart Fail Rev; 2009 Dec; 14(4):265-75. PubMed ID: 19101796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.